HCFA ADMINISTRATOR NOMINEE VLADECK WOULD BRING BOTH ADMINISTRATIVE AND POLICY
This article was originally published in The Gray Sheet
Executive SummaryHCFA ADMINISTRATOR NOMINEE VLADECK WOULD BRING BOTH ADMINISTRATIVE AND POLICY backgrounds to the top position at the Health Care Financing Administration at a time when Congress and President Clinton are focused on cutting health care costs. The White House announced Bruce Vladeck's nomination for the position of HCFA administrator on March 5. Vladeck, 43, has been president of the United Hospital Fund of New York since 1983, directing the fund's involvement in grant-making, health services research and policy development. Vladeck also is a director of the New York City Health and Hospitals Corporation. Additionally, he serves as co-chair of the New York State Council on Health Care Financing. At the national level, Vladeck has served on the federal Medicare Prospective Payment Assessment Commission since 1986, chairing ProPAC's Subcommittee on Hospital Inpatient Services. He was acting ProPAC chairman during the Clinton transition period while Stuart Altman headed a health care policy development group for the incoming administration. Before joining the United Hospital Fund of New York, Vladeck was assistant VP of the Robert Wood Johnson Foundation. From 1979 until 1982, he was assistant commissioner for health planning and resources development of the New Jersey State Department of Health. A good portion of his experience is in regulatory-oriented programs. For example, Vladeck directed the State Health Planning and Development Agency, where he oversaw the implementation of New Jersey's all-payer, DRG-based hospital prospective payment system. Vladeck received a BA in government from Harvard and an MA and PhD in political science from the University of Michigan. From 1974 to 1979, he was an assistant and associate professor of public health and political science at Columbia University. Among his many advisory affiliations, Vladeck is a member of New York State's AIDS Advisory Council and the Governor's Health Care Advisory Board. He published a book entitled Unloving Care: The Nursing Home Tragedy.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.